Article
Immunology
Mark Anderson, Jeffery Gersch, Ka-Cheung Luk, George Dawson, Ivana Carey, Kosh Agarwal, Pir Shah, Geoffrey Dusheiko, Daryl Lau, Gavin Cloherty
Summary: The study found that full-length pregenomic RNA is the primary source of circulating HBV RNA in infected patients, clarifying the major identity of HBV RNA species in circulation.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Xiu-Mei Chi, Xiao-Mei Wang, Zhong-Feng Wang, Rui-Hong Wu, Xiu-Zhu Gao, Hong-Qin Xu, Yan-Hua Ding, Jun-Qi Niu
Summary: The study found that serum qHBcrAg levels were correlated with virological markers of HBV in patients with chronic hepatitis B, and could be used to predict HBeAg seroconversion.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Virology
Andreas Laras, Margarita Papatheodoridi, Eleni Panopoulou, George Papatheodoridis, Stephanos J. Hadziyannis, Emilia Hadziyannis
Summary: Serum HBV RNA in HBeAg-negative chronically infected patients primarily consists of pgRNA and a minor fraction of preC mRNA transcripts. Serum pgRNA is associated with disease activity and can serve as a marker for the decision of cessation of therapy.
Article
Public, Environmental & Occupational Health
Hao-Zhen Yan, Zhi-Hao Huang, Xu-Guang Guo, Ting-Ting Peng, Li-Li Yang, Chong-Wen Liu, Shi Ou-Yang
Summary: This study investigated the influencing factors and change magnitude of pgRNA based on real-world data. The results showed that positive HBV DNA and HBeAg were independent risk factors for positive pgRNA, and age had an impact on the change magnitude of pgRNA. There was a significant correlation between pgRNA and liver fibrosis, and different treatment regimens and disease stages had different effects on pgRNA status.
FRONTIERS IN PUBLIC HEALTH
(2022)
Review
Gastroenterology & Hepatology
Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho
Summary: Hepatitis B virus (HBV) infection is a serious global public health problem, and there is currently no complete cure. The focus of recent research has been on achieving a functional cure for HBV through combination therapies and immunomodulators. New therapeutic approaches and clinical trials are being conducted to find a long-lasting cure for HBV infection.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Article
Virology
Meng-Lan Wang, Juan Liao, Feng Ye, Ya-Chao Tao, Dong-Bo Wu, Min He, Hong Tang, En-Qiang Chen
Summary: This study found strong correlation between serum HBV pgRNA and HBcrAg levels in Chinese chronic hepatitis B patients, with moderate correlation with HBV DNA and HBsAg. Differences in serum HBV pgRNA levels and correlations were observed between HBeAg-positive and HBeAg-negative patients, with HBcrAg showing the most stable correlation with HBV pgRNA.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Medicine, General & Internal
Man-Fung Yuen, Seng-Gee Lim, Robert Plesniak, Keiji Tsuji, Harry L. A. Janssen, Cristina Pojoga, Adrian Gadano, Corneliu P. Popescu, Tatyana Stepanova, Tarik Asselah, Gheorghe Diaconescu, Hyung Joon Yim, Jeong Heo, Ewa Janczewska, Alexander Wong, Nevin Idriz, Michio Imamura, Giuliano Rizzardini, Koichi Takaguchi, Pietro Andreone, Manuela Arbune, Jinlin Hou, Sung Jae Park, Andrei Vata, Jennifer Cremer, Robert Elston, Tamara Lukic, Geoff Quinn, Lauren Maynard, Stuart Kendrick, Helene Plein, Fiona Campbell, Melanie Paff, Dickens Theodore, B-Clear Study Grp
Summary: Bepirovirsen treatment for 24 weeks at a dose of 300 mg per week resulted in sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA in 9%-10% of patients with chronic HBV infection. Larger and longer trials are needed to assess the efficacy and safety of bepirovirsen.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Jiali Pan, Yu Tian, Jinghang Xu, Hao Luo, Ning Tan, Yifan Han, Qian Kang, Hongyu Chen, Yuqing Yang, Xiaoyuan Xu
Summary: This study explores the long-term dynamics of serum HBV pgRNA in patients with chronic hepatitis B. The positive rates of HBV pgRNA gradually decline and show biphasic kinetics. Patients treated with entecavir have a later HBV pgRNA seroconversion. Patients who remain positive for HBV pgRNA after 9 years of treatment may have higher viral transcription efficiencies.
FRONTIERS IN MEDICINE
(2022)
Review
Virology
Yang Shi, Zihan Wang, Shengxiang Ge, Ningshao Xia, Quan Yuan
Summary: The HBcAg is a highly immunogenic antigen and the anti-HBc is traditionally considered as a serological marker of HBV infections. However, recent studies have shown the predictive value of quantitative anti-HBc level in the treatment response and clinical outcome of chronic HBV infections. This review summarizes the clinical values of qAnti-HBc in differentiating CHB phases, predicting treatment response, and providing disease prognosis.
Article
Microbiology
I-Chin Wu, Wen-Chun Liu, Yen-Cheng Chiu, Hung-Chih Chiu, Pin-Nan Cheng, Ting-Tsung Chang
Summary: Serum HBV pgRNA kinetics during treatment and around HBsAg loss show varied patterns, with most patients maintaining detectable levels of pgRNA even after achieving HBsAg loss. Baseline serum HBV pgRNA alone is insufficient for predicting the trajectory of HBV pgRNA. Further studies on HBV pgRNA kinetics around HBsAg loss would provide valuable insights for future applications of HBV pgRNA.
Article
Multidisciplinary Sciences
Pakkapon Rattanachaisit, Sirinporn Suksawatamnuay, Supachaya Sriphoosanaphan, Kessarin Thanapirom, Panarat Thaimai, Nipaporn Siripon, Sukanya Sittisomwong, Yong Poovorawan, Piyawat Komolmit
Summary: This study evaluated the stability of HBV pgRNA under different temperature conditions and storage durations. The results showed that pgRNA levels remained stable at 4 degrees C and room temperature for at least 48 hours, as well as under multiple freeze-thaw cycles.
Article
Gastroenterology & Hepatology
Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S. Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson
Summary: A meta-analysis was conducted on clinical outcomes after nucleot(s)ide analogue (NA) discontinuation for HBeAg-negative CHB patients, revealing that virological relapse is common but clinical relapse occurs in only one-third of patients at 12 months post-NA discontinuation. Discontinuation of NA therapy can lead to HBsAg clearance, with higher rates observed with longer follow-up periods.
Article
Gastroenterology & Hepatology
Ayato Murata, Kiyohiko Angata, Maki Sogabe, Shunsuke Sato, Takafumi Ichida, Hisashi Narimatsu, Takuya Genda
Summary: This study evaluated the changes in serum HBsAg levels in patients with chronic hepatitis B (CHB) treated with nucleos(t)ide analogs (NAs). The results showed that the serum levels of O-glycosylated HBsAg were correlated with viral load markers and changed after NA therapy. This suggests that an O-glycosylated HBsAg-based immunoassay may serve as a novel approach to monitor viral kinetics during treatment.
BMC GASTROENTEROLOGY
(2022)
Review
Virology
Manasa Suresh, Stephan Menne
Summary: Infection with hepatitis B virus (HBV) is a global burden, and finding a cure for this viral disease is challenging. Animal models play a crucial role in studying gene expression and viral inhibition, and are significant for clinical trials.
Article
Gastroenterology & Hepatology
Hye-Lin Kim, Gi-Ae Kim, Jae-A Park, Hye-Rim Kang, Eui-Kyung Lee, Young-Suk Lim
Summary: This study found that starting antiviral therapy in the immune-tolerant phase is more cost-effective compared with delaying treatment until the active hepatitis phase in CHB patients, especially with increasing hepatocellular carcinoma risk, decreasing drug costs, and consideration of productivity loss.
